Hagop Kantarjian: New research is expanding inotuzumab use into frontline, for MRD+, and in combination with blinatumomab
Nicholas Short, Associate Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post by Hagop Kantarjian on X, adding: .
“Our new review on inotuzumab ozogamicin is now online. We cover the clinical development of INO, pivotal studies, and the novel uses of INO in B-ALL, including combination therapies and use in the frontline setting.”
Quoting Hagop Kantarjian’s post:
“Inotuzumab approved as monotherapy for R/R ALL but new research is expanding its use into frontline, for MRD+, and in combo with blinatumomab. Best outcomes seen in combinations.”
Read further.
Source: Nicholas Short/X and Hagop Kantarjian/X
Hagop Kantarjian is the professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he also serves as the Samsung Distinguished Leukemia Chair in Cancer Medicine.
Dr. Kantarjian’s research focuses on translational-clinical developmental therapeutics in leukemia, spanning over four decades. His contributions include advancements in chronic myeloid leukemia treatment, such as tyrosine kinase inhibitors like imatinib, dasatinib, nilotinib, and bosutinib.
Moreover, he has made discoveries in acute lymphocytic leukemia, myelodysplastic syndrome, and leukemias treatment, resulting in over 20 FDA-approved drugs.